Abstract
Numerous analyses demonstrate that antihypertensive therapies promote development of type-2 diabetes mellitus. This is particularly true in obesity patients with impaired glucose tolerance. Numerous randomized studies provide evidence that the use of diuretics and β blockers produces the highest risk for conversion to diabetes, whereas angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARB) lead to less new-onset diabetes compared to placebo. β Blockers worsen glycemic control through worsening of insulin resistance and reduced flow to muscle whereas diuretics impair glucose metabolism, in part, through reducing potassium. Thus, diuretics and β blockers not only increase glucose in those with diabetes but also promote the development of new-onset diabetes in those with glucose intolerance. Given the latest guidelines, β blockers are not indicated for routine use to treat hypertension and diuretics should be reserved for second- or third-line agents. Data from the NICE guidelines in the United Kingdom put diuretics as third-line agents after blockers of the renin–angiotensin system and calcium antagonists. One must keep in mind, however, that in multiple trials where diuretics were shown to worsen glycemic control, there was a mortality benefit as increasing doses of oral hypoglycemic medications were used. In short, while these agents can be avoided as initial agents for treatment of hypertension, many patients with heart or kidney disease, i.e., eGFR < 60 mL/min, will require diuretic therapy to control blood pressure.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. J Am Med Assoc. 2003;289(19):2560–72.
Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217–23.
King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21(9):1414–31.
Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med. 2000;342(13):905–12.
Izzo R, de Simone G, Chinali M, et al. Insufficient control of blood pressure and incident diabetes. Diabetes Care. 2009;32(5):845–50.
Kramer CK, von MD, Barrett-Connor E. Mid-life blood pressure levels and the 8-year incidence of type 2 diabetes mellitus: the Rancho Bernardo Study. J Hum Hypertens. 2010;24(8):519–24.
Lindholm LH, Ibsen H, Borch-Johnsen K, et al. Risk of new-onset diabetes in the Losartan Intervention for Endpoint reduction in hypertension study. J Hypertens. 2002;20(9):1879–86.
Niklason A, Hedner T, Niskanen L, Lanke J. Development of diabetes is retarded by ACE inhibition in hypertensive patients–a subanalysis of the Captopril Prevention Project (CAPPP). J Hypertens. 2004;22(3):645–52.
Gupta AK, Dahlof B, Dobson J, Sever PS, Wedel H, Poulter NR. Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm and the relative influence of antihypertensive medication. Diabetes Care. 2008;31(5):982–8.
Aksnes TA, Kjeldsen SE, Rostrup M, Storset O, Hua TA, Julius S. Predictors of new-onset diabetes mellitus in hypertensive patients: the VALUE trial. J Hum Hypertens. 2008;22(8): 520–7.
Sarafidis PA, Bakris GL. Antihypertensive therapy and the risk of new-onset diabetes. Diabetes Care. 2006;29(5):1167–9.
Sarafidis PA, Bakris GL. Do the metabolic effects of beta blockers make them leading or supporting antihypertensive agents in the treatment of hypertension? J Clin Hypertens (Greenwich). 2006;8(5):351–6.
Lithell HO. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care. 1991;14(3):203–9.
Taylor EN, Hu FB, Curhan GC. Antihypertensive medications and the risk of incident type 2 diabetes. Diabetes Care. 2006;29(5):1065–70.
Grimm C, Koberlein J, Wiosna W, Kresimon J, Kiencke P, Rychlik R. New-onset diabetes and antihypertensive treatment. GMS Health Technol Assess. 2010;6:Doc03.
Bangalore S, Parkar S, Grossman E, Messerli FH. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol. 2007;100(8):1254–62.
Bakris G, Molitch M, Hewkin A, et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care. 2006;29(12):2592–7.
Bakris G, Molitch M, Zhou Q, et al. Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET study. J Cardiometab Syndr. 2008;3(1):18–25.
Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs. 2004;64(22):2537–65.
Gillespie EL, White CM, Kardas M, Lindberg M, Coleman CI. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care. 2005;28(9):2261–6.
Bosch J, Yusuf S, Gerstein HC, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006;355(15):1551–62.
Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med. 2004;141(6):413–20.
Khaw KT, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk). Br Med J. 2001;322(7277):15–8.
Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4):229–34.
Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005;165(12):1410–9.
Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension. 2004;43(5):963–9.
Dunder K, Lind L, Zethelius B, Berglund L, Lithell H. Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction: population based cohort study. Br Med J. 2003;326(7391):681.
Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol. 2005;95(1):29–35.
Barzilay JI, Davis BR, Cutler JA, et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2006;166(20):2191–201.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media New York
About this chapter
Cite this chapter
Lazich, I., Bakris, G.L. (2012). Antihypertensive Therapy and New-Onset Diabetes. In: McFarlane, S., Bakris, G. (eds) Diabetes and Hypertension. Contemporary Diabetes. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60327-357-2_10
Download citation
DOI: https://doi.org/10.1007/978-1-60327-357-2_10
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-60327-356-5
Online ISBN: 978-1-60327-357-2
eBook Packages: MedicineMedicine (R0)